Spectrum Solutions  

12278 S Lone Peak Pkwy
Draper,  UT  84020

United States
https://spectrumsolution.com/
  • Booth: 5228

Headquartered in Salt Lake City, UT, Spectrum Solutions is a healthcare solutions partner striving to bridge the gap between science and real medical solutions. Our laboratory products and services, clinical testing, and onsite compounding pharmacy are driving decentralized testing, accelerating multi-omic scientific applications, modernizing direct-to-consumer wellness, and delivering innovation with the practical power to impact and change outcomes.


 Press Releases

  • PRESS RELEASE
    Leslie Titus Bryant
    March 19, 2024

    SALT LAKE CITY—March 19, 2024—Spectrum Solutions® today announced the official release of a new saliva diagnostic testing innovation, SimplyPERIO™. As advances in science and whole health understanding continue to focus in on the mouth-body connection and its direct link to systemic disease, SimplyPERIO™ fills a testing void by delivering more intelligent health measures with real clinical relevance using 16 oral targets from a single patient sample.

    Gum disease, also called periodontal disease, is the most undiagnosed and untreated disease with the highest impact to so many bodily systems and functions. In addition, gum disease decreases a person’s ability to fight infection and inflammation.

    In the U.S., numbers illustrate that 80% of individuals over 35 have a form of gum disease. Gingivitis, periodontitis, and peri-implantitis are all forms of gum disease. These numbers demonstrate that for the vast majority, there may be dangerous and damaging periodontal disease pathogens hiding that can’t be identified with a perio-probe or visual exam during regular semi-annual cleanings. Gone unchecked, these harmful oral bacteria and toxins are allowed to sit and accumulate inside the mouth. From inside the mouth, these microorganisms move freely to and through the bloodstream with far-reaching and catastrophic effects on the heart, arteries, central nervous system, and more.

    SimplyPERIO™ uses a proprietary molecular technology to test for and measure periodontal bacteria, caries, fungal, and viral targets all for one affordable cost. Understanding treatment success is often influenced by host immunity and host response, this unique, highly sensitive and highly specific saliva test offers Providers the real opportunity to elevate patient care with the most complete oral health picture.

    “We are using science to make saliva diagnostics simple for both Patients and Providers. SimplyPERIO™ testing is not only pain-free, it takes less than 30 seconds for a patient to collect their own sample,” said Dr. David Vigerust, PhD, Chief Science Officer at Spectrum Solutions. “In addition, our CAP-accredited laboratory delivers Providers the independent, 3rd party results necessary for intelligent, data-supported patient conversations about stopping and even reversing their disease and systemic risks.”

    The SimplyPERIO™ patented blue buffer solution located inside the collection device’s cap stabilizes saliva samples at room temperature, eliminating any special post-collection storage or shipping requirements. Easily deposit one at a time, supporting at-home patient testing for follow-up and treatment monitoring, or gather an entire day’s worth of in-office collections into the USPS postage-paid return box for mailing samples back to the lab for processing.

    __________

    Click here to view this press release on the Business Wire.

  • PRESS RELEASE
    Leslie Titus Bryant
    March  07, 2023

    Spectrum Solutions’ offerings enhanced by including CLIA/CAP laboratory testing, custom assay development, and manufacturing of industry-leading microarray chip technology.

    SALT LAKE CITY, UTAH—Spectrum Solutions® today announced the acquisitions of Alimetrix, Inc., a CLIA and CAP accredited molecular diagnostic laboratory skilled at custom qualitative and quantitative assay development, and Microarrays, Inc., a leader in customer array-based products that are used as biological research tools – gene expression arrays, reverse and forward phase protein arrays.

    These valuable assets, combined with Spectrum Solutions core competencies of providing industry-leading contract manufacturing services and unique biospecimen collection devices, creates a unique synergistic relationship resulting in a portfolio of products and services that enhances the overall patient testing experience whether in a clinical setting or at home. Alimetrix, Inc.’s molecular laboratory capabilities and Microarrays, Inc.’s expertise in manufacturing array-based products, now coupled with Spectrum’s capabilities creates a comprehensive suite of products and services accelerating Spectrum’s go-to-market strategies.

    Spectrum’s core business divisions include:

    • Spectrum LabServices™, including innovative assay development, contract manufacturing, and clinical testing business support services.
    • Spectrum SimplyTest™, a family of validated, highly sensitive multiplex laboratory-developed tests for both direct-to-consumer and physician-directed testing.
    • Spectrum Compounding RX™ Pharmacy, an onsite, multi-state licensed patient-specific compounding pharmacy partner with direct-to-patient dispensing capabilities.

    “The acquisitions of Alimetrix and Microarrays not only enhances Spectrum’s portfolio to include high-impact laboratory testing and custom assay services, it also serves to advance patient care and clinical research,” said Stephen Fanning, CEO at Spectrum Solutions. “Spectrum is now one step closer to its vision of developing a transformative, decentralized healthcare platform aimed at innovating the way biospecimens are collected and laboratory testing is conducted.”

    “At Alimetrix and Microarrays, our mission has always been dedicated to performing work bigger than ourselves that enables positive change in the world through science. Joining forces with a scientifically committed company like Spectrum will extend and enhance our capabilities to the masses and help individuals and communities take control of their health,” said Joel Peek, President and Chief Science Officer at Alimetrix and Microarrays.

    Click here to view this press release on the Business Wire.

  • PRESS RELEASE
    Leslie Titus Bryant
    February  22, 2023

    SALT LAKE CITY, UTAH—Spectrum Solutions, LLC today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) Class II clearance to the SDNA Saliva Collection Device as a microbial nucleic acid storage and stabilization device.

    The SDNA device is driving a new era of healthcare that turns to salivary collection and preservation as a means to detect viral infections and resolve the most common points of failure associated with whole saliva. The device is heralded for its ability to maximize detection at the lowest levels and neutralize viruses within 10 seconds of collection to mitigate unnecessary viral exposure. The company’s patented preservation media keeps analytes stable for many weeks at ambient temperatures, ensuring safe, easy, and secure specimen storage and transport. To ensure the highest degree of stringency and quality, automated methods for extraction and validation were performed on industry-leading platforms.

    Near the beginning of the pandemic, Spectrum’s SDNA-1000 was the first to gain FDA Emergency Use Authorization (EUA) and introduce a nation, held under viral siege, to the noninvasive, highly accurate, and earliest detection benefits of COVID-19 testing using the self-collection of saliva. With over two years of processing SARS-CoV-2 saliva tests, the device and its patented nucleic acid preservation chemistry have not only demonstrated but proven their unique and superior capabilities deserving of this new device clearance.

    “This 510(k) clearance and certification as an IVD molecular diagnostic device enables physicians, hospitals, researchers, and others to leverage our SDNA Saliva Collection Device in a broad array of FDA-cleared and LDT diagnostic testing applications,” said Stephen Fanning, CEO at Spectrum Solutions. “Those conducting screening and diagnostic tests can confidently and safely expand access and opportunity incorporating saliva as a primary or alternative biomaterial into their existing testing protocols.”

    “We couldn’t be more excited for the opportunity this new 510(k) device clearance delivers in supporting laboratory medicine and healthcare systems in safely and confidently decentralizing specimen collections for precise and accurate testing,” said Chief Medical Officer, Rohit Gupta, at Spectrum Solutions.

    Click here to view this press release on the Business Wire.

  • PRESS RELEASE
    Leslie Titus Bryant
    July 26, 2022

    SALT LAKE CITY, UTAH—Spectrum Solutions, LLC today announced the publishing of findings from their research collaboration with the University of California at Los Angeles (UCLA) and Dr. David Wong, UCLA School of Dentistry. The project has successfully demonstrated a superior ability to detect circulating tumor DNA (ctDNA) from saliva. Specifically, amplified EGFR mutations associated with non-small cell lung cancer (NSCLC) using Spectrum’s saliva collection and preservation system with the Electric Field–Induced Release and Measurement (EFRIM) electrostatic platform.

    Most lung cancers (85 percent) fall into the category called non-small cell lung cancer (NSCLC). Though this form of lung cancer progresses more slowly than small cell lung cancer (SCLC), 40 percent of those living with NSCLC will have it spread beyond the lungs by the time it is diagnosed. Many advances in targeted treatments for lung cancer are based on the evaluation of three EGFR gene mutations. Current methods for diagnosis and monitoring include invasive tissue biopsies, which create clinical obstacles for ongoing mutation analysis and cancer treatment. The less invasive liquid biopsy options using free-floating cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) in solid tumor cancers have quickly become an important part of the screening, diagnosis, and monitoring process for cancer patients.

    “The ability to detect EGFR mutations using ctDNA enables a broad range of clinical applications such as the early detection of disease, practical applications of personalized treatments, predicting treatment response, and monitoring resistance,” said Rohit Gupta, Chief Medical Officer for Spectrum Solutions. “Proving it can be done using saliva is groundbreaking.”

    The ctDNA associated with NSCLC, termed ‘ultra-short’ ctDNA (usctDNA), is a third smaller in size than the average fragment. This has made it extremely hard to detect using current liquid biopsy technology, especially without additional amplification. Prior to this study, Wong’s team published on the successful detection of the same usctDNA EGFR mutations from both early and late-stage patients living with NSCLC in both blood and saliva. When paired with new technology developed at UCLA by Dr. Wong, known as EFIRM, study findings have demonstrated an impressive 14-fold amplification of detectable usctDNA from saliva collected and stabilized using Spectrum’s SDNA-1000 compared to raw or neat saliva. Additionally, after diluting the signal down to 10 percent of the original concentration, the team continued to see enhanced amplification benefits from the Spectrum device, leading scientists to believe detection of a single ctDNA fragment may now be possible.

    “Achieving detectable concentrations of ctDNA in body fluids is not an easy task. The significance of successfully demonstrating this capability with saliva is the holy grail of liquid biopsy research,” said Dr. David Wong, UCLA School of Dentistry. “The discovery delivers, for the first time, a noninvasive opportunity for detection and the ongoing ‘real-time’ understanding of somatic mutation activity to direct and redirect successful treatment strategies.”

    “Understanding how many face the likelihood of treatment resistance, it is actually life-changing to know the results from this research collaboration with Dr. Wong and UCLA has real power to positively impact patient outcomes,” said Steve Fanning, CEO of Spectrum Solutions. “For patients, the ability to use the self-collection of saliva empowers a new, safer, easier and pain-free era of detection and treatment innovation with real at-home remote care possibilities.”

    Are you interested in learning more about integrating saliva into your current research or testing programs? Click here to find out more about integrating and understanding saliva-based diagnostics.

  • SALT LAKE CITY, UTAH—Spectrum Solutions® today announced the acquisitions of Alimetrix, Inc., a CLIA and CAP accredited molecular diagnostic laboratory skilled at custom qualitative and quantitative assay development, and Microarrays, Inc., a leader in customer array-based products that are used as biological research tools – gene expression arrays, reverse and forward phase protein arrays.

    These valuable assets, combined with Spectrum Solutions core competencies of providing industry-leading contract manufacturing services and unique biospecimen collection devices, creates a unique synergistic relationship resulting in a portfolio of products and services that enhances the overall patient testing experience whether in a clinical setting or at home. Alimetrix, Inc.’s molecular laboratory capabilities and Microarrays, Inc.’s expertise in manufacturing array-based products, now coupled with Spectrum’s capabilities creates a comprehensive suite of products and services accelerating Spectrum’s go-to-market strategies.

    Spectrum’s core business divisions include:

    • Spectrum LabServices™, including innovative assay development, contract manufacturing, and clinical testing business support services.
    • Spectrum SimplyTest™, a family of validated, highly sensitive multiplex laboratory-developed tests for both direct-to-consumer and physician-directed testing.
    • Spectrum Compounding RX™ Pharmacy, an onsite, multi-state licensed patient-specific compounding pharmacy partner with direct-to-patient dispensing capabilities.
    • “The acquisitions of Alimetrix and Microarrays not only enhances Spectrum’s portfolio to include high-impact laboratory testing and custom assay services, it also serves to advance patient care and clinical research,” said Stephen Fanning, CEO at Spectrum Solutions. “Spectrum is now one step closer to its vision of developing a transformative, decentralized healthcare platform aimed at innovating the way biospecimens are collected and laboratory testing is conducted.”

      “At Alimetrix and Microarrays, our mission has always been dedicated to performing work bigger than ourselves that enables positive change in the world through science. Joining forces with a scientifically committed company like Spectrum will extend and enhance our capabilities to the masses and help individuals and communities take control of their health,” said Joel Peek, President and Chief Science Officer at Alimetrix and Microarrays.